Jubilant HollisterStier Announces First FDA Commercial Product Approval for Sterile Fill-Finish Line 3
The achievement reflects the successful expansion of JHS’s sterile injectable manufacturing capabilities and continued growth at its Spokane site.
Jubilant HollisterStier (JHS) is pleased to announce the FDA regulatory approval of the first commercial sterile injectable product manufactured on its Line 3 isolator fill-finish line, marking a major milestone for the company’s expanded manufacturing operations at its Spokane facility.
“The first FDA commercial product approval on Line 3 is a significant achievement for our team and demonstrates our continued growth,” said Chris Preti, CEO of JHS. “We look forward to building on that momentum as Line 4 progresses toward completion.”
As JHS continues to invest in sterile manufacturing capabilities, the company’s $300M+ major expansion project is on track for completion in 2026 and will further increase capacity for manufacturing complex liquid and lyophilized sterile injectables.
About Jubilant HollisterStier
Jubilant HollisterStier CMO provides comprehensive sterile fill-finish and lyophilization services, ensuring the consistent delivery of high-quality products that meet the needs of global healthcare markets and patients worldwide. With decades of experience, we offer a flexible and collaborative partnership model for manufacturing excellence that enables our clients to increase speed to market with full regulatory confidence.
###
Media Contact
Sarah Dolan, Marketing Manager | Sarah.Dolan@jubl.com
